Table 1.
Clinical features of Patients with PTB and CAP.
| features | All Cohort | Training Cohort | Testing Cohort | Validation Cohort | ||||
|---|---|---|---|---|---|---|---|---|
| CAP | PTB | CAP | PTB | CAP | PTB | CAP | PTB | |
| n | 163 | 195 | 74 | 96 | 32 | 41 | 58 | 57 |
| Sex (%) | ||||||||
| Female | 86 (24%) | 79 (22.1%) | 45 (26.5%) | 40 (23.5%) | 12 (16.4%) | 11 (15.1%) | 30 (26.1%) | 28 (24.3%) |
| Male | 77 (21.5%) | 116 (32.4%) | 29 (17.1%) | 56 (32.9%) | 20 (27.4%) | 30 (41.1%) | 28 (24.3%) | 29 (25.2%) |
| Age | 51 (31, 67) | 61 (46, 71.5) | 49 (30.25, 66) | 62 (41, 73) | 52 (35.75, 66.25) | 64 (49, 70) | 60 (42.25, 69.75) | 52 (31, 67) |
| WBC | 6.26 (4.93, 8.20) | 7.19 (5.54, 9.36) | 6.26 (4.51, 8.70) | 7.20 (5.57, 9.35) | 5.97 (5, 7.44) | 6.92 (4.99, 8.97) | 7.64 ± 2.92 | 7.12 ± 2.88 |
| NEUT% | 64.2 (55.8, 74.75) | 72.64 (63.95, 81.01) | 64.49 ± 14.63 | 71.38 ± 11.92 | 64.32 ± 12.17 | 72.81 ± 11.96 | 72.26 ± 10.70 | 66.53 ± 14.73 |
| LYMPH% | 25.8 (16.35, 32.15) | 15.54 (11.4, 24.75) | 24.9 (16.16, 35.06) | 16.5 (11.65, 24.88) | 27.3 (20.49, 31.83) | 14.9 (8.8, 24.7) | 15.52 (11.55, 24.48) | 23.5 (14.84, 31) |
| HGB | 122 (110.5, 134) | 114 (100.5, 125) | 120.5 (111, 131) | 114.5 (101, 126.25) | 125.47 ± 16.629 | 114.12 ± 20.44 | 113 (98, 122.5) | 124 (110, 134) |
| PLT | 217 (183, 290) | 247 (204.5, 334) | 215.5 (174.25, 290) | 233.5 (195.5, 318.25) | 218.56 ± 56.786 | 288.9 ± 126.4 | 254 (221, 337.75) | 235 (196, 303) |
| ALB | 37.93 ± 6.17 | 34.86 ± 5.63 | 38.51 ± 6.01 | 35.11 ± 5.18 | 38.4 (34.28, 41.53) | 33.9 (30.4, 37.9) | 35.10 ± 5.81 | 37.37 ± 6.48 |
| GLU | 5.33 (4.73, 6.04) | 5.06 (4.56, 5.79) | 5.33 (4.65, 6.14) | 4.985 (4.54, 5.54) | 5.21 (4.76, 5.77) | 5.12 (4.56, 6.13) | 5.09 (4.6, 5.76) | 5.41 (4.97, 6.17) |
| CRP | 22.1 (2.81, 76.89) | 28.2 (7.45, 70.05) | 18.19 (2.98, 66.04) | 28.78 (6.30, 54.83) | 16.4 (1.35, 61.36) | 24.4 (7.4, 77.7) | 28.64 (9.5, 71.95) | 36.1 (3.44, 83.1) |
| T-SPOT, (%) | ||||||||
| negative | 129 (36%) | 42 (11.7%) | 62 (36.5%) | 19 (11.2%) | 23 (31.5%) | 7 (9.6%) | 16 (13.9%) | 44 (38.3%) |
| Positive | 34 (9.5%) | 153 (42.7%) | 12 (7.1%) | 77 (45.3%) | 9 (12.3%) | 34 (46.6%) | 42 (36.5%) | 13 (11.3%) |
| Fever, (%) | ||||||||
| ≥37.3°C | 122 (34.1%) | 67 (18.7%) | 53 (31.2%) | 35 (20.6%) | 26 (35.6%) | 10 (13.7%) | 36 (31.3%) | 14 (12.2%) |
| <37.3°C | 41 (11.5%) | 128 (35.8%) | 21 (12.4%) | 61 (35.9%) | 6 (8.2%) | 31 (42.5%) | 22 (19.1%) | 43 (37.4%) |
| Cough,(%) | ||||||||
| Yes | 139 (38.8%) | 163 (45.5%) | 12 (7.1%) | 17 (10%) | 26 (35.6%) | 35 (47.9%) | 9 (7.8%) | 6 (5.2%) |
| No | 24 (6.7%) | 32 (8.9%) | 62 (36.5%) | 79 (46.5%) | 6 (8.2%) | 6 (8.2%) | 49 (42.6%) | 51 (44.3%) |
| Expectoration,(%) | ||||||||
| Yes | 109 (30.4%) | 151 (42.2%) | 25 (14.7%) | 23 (13.5%) | 20 (27.4%) | 30 (41.1%) | 10 (8.7%) | 17 (14.8%) |
| No | 54 (15.1%) | 44 (12.3%) | 49 (28.8%) | 73 (42.9%) | 12 (16.4%) | 11 (15.1%) | 48 (41.7%) | 40 (34.8%) |
| Hemoptysis,(%) | ||||||||
| No | 132 (36.9%) | 140 (39.1%) | 61 (35.9%) | 69 (40.6%) | 22 (30.1%) | 32 (43.8%) | 39 (33.9%) | 49 (42.6%) |
| Yes | 31 (8.7%) | 55 (15.4%) | 13 (7.6%) | 27 (15.9%) | 10 (13.7%) | 9 (12.3%) | 19 (16.5%) | 8 (7%) |
The data of normal distribution were described as mean ± standard deviation (SD) compared by t test. Data that are not normally distributed were expressed as median (range interquartile) and analyzed using the rank-sum test.
WBC, white blood cell count; NEUT%, neutrophil ratio; LYMPH%, neutrophil to lymphocyte ratio; CRP, C-reactive protein; HGB, Hemoglobin; PLT, platelets; ALB, albumin; GLU, glucose.